Company Summary - Pag Biopharma-B (02565) saw its stock price increase by over 15%, reaching a new high of 24.14 HKD during trading, and currently trading at 23.24 HKD with a transaction volume of 20.32 million HKD [1] - The company’s drug PB-119, aimed at treating Type 2 Diabetes Mellitus (T2DM), is expected to receive NDA approval in 2025 and will be commercialized in China [1] - PB-119 has also initiated Phase Ib/IIa clinical trials for obesity treatment, with participant recruitment expected to be completed by June 2024 [1] - Pag Biopharma is exploring the potential of PB-119 in combination therapies to expand its range of indications [1] Industry Insights - The weight loss drug market has gained significant traction, particularly with GLP-1 receptor agonists like semaglutide becoming popular globally [1] - Analysts from CITIC Securities indicate that weight loss consumption has characteristics of self-indulgent spending, which can lead to the emergence of blockbuster products [1] - With overseas companies like Novo Nordisk and Eli Lilly exceeding performance expectations and accelerated domestic R&D progress, the trend in the weight loss drug industry is expected to become clearer [1] - The domestic weight loss drug market is anticipated to grow rapidly as more related drugs receive approval [1]
港股异动 派格生物医药-B(02565)午后涨超15%破顶 PB-119用于治疗T2DM预计将于年内获NDA批准